A Phase 2 Study of Risvodetinib in Untreated Parkinson’s Disease
Objective: Risvodetinib was evaluated in a randomized, double-blind, placebo controlled Phase 2 trial at three doses to determine the safety and tolerability in patients with…Disease Modifying Potential of a Novel ROCK Inhibitor in Rodent Models of Synucleinopathy
Objective: Evaluate the impact of a novel Rho-associated kinase (ROCK) inhibitor on alpha-synuclein (a-syn) pathology, neuroinflammation, and dopamine neurodegeneration in the AAV-a-syn overexpression and a-syn…Molecular Studies Reveal Overactive Interferon (IFN) Pathway in Two Monogenic Inherited Dystonia Types.
Objective: Our overall objective was to investigate the involvement of type I interferons (IFNs) in DYT-PRKRAand DYT-EIF2AK2. IFNs are antiviral cytokines produced by all cell…The 201 Trial in Untreated Parkinson’s Disease
Objective: To evalute the safety, tolerability, clinical benefit and protein pathology status following risvodetinib (IkT-148009) treatment in participants with untreated Parkinson's disease. Background: RIsvodetinib is…Neurotinib, a Brain Penetrant c-Abl Inhibitor, Prevents Activation and Phosphorylation of c-Abl Kinase and Alpha-Synuclein
Objective: Objective: To investigate Neurotinib, a newly developed allosteric c-Abl inhibitor, as a neuroprotective agent in a murine GBA1-associated Parkinson's disease (PD) model. Background: The…Gut Microbiota May Alter Glucose Metabolism in Patients with Parkinson’s Disease
Objective: To compare the gut microbiota in patients with Parkinson’s disease (PD) and healthy controls and predict the functional pathways associated with these differences. Background:…Cognitive Outcome in Pantothenate Kinase-Associated Neurodegeneration (PKAN) Treated with Deep Brain Stimulation (DBS):Case Report
Objective: To assess cognitive outcome in PKAN treated with DBS Background: PKAN is a rare neurodegenerative disorder with pediatric onset & dystonic features. Motor symptoms…Analysis of the therapeutic potential of c-Abl inhibition in Multiple System Atrophy
Objective: IkT-148009 is a potent selective inhibitor of non-receptor Abelson Tyrosine Kinases (c-Abl kinases). Our recent analysis of post-mortem brain tissue from patients with Multiple…Analysis of the therapeutic potential of IkT-148009 in Parkinson’s disease
Objective: To evaluate the therapeutic potential of the selective, brain penetrant c-Abl inhibitor IkT-148009 in mouse models of progressive PD and the safety and tolerability…Neuroprotective effects of Ibudilast, a Phosphodiesterase IV inhibitor in mouse model of Parkinson’s disease
Objective: In the present study, we examined neuroprotective effects, if any, of IBD drug, a inhibitor of the phosphodiesterase IV in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.